Q4 2024 Management View CEO Raymond Tesi highlighted the transformative potential of 2024 for INmune Bio, emphasizing upcoming milestones. He noted the Phase 2 trial of XPro for Alzheimer's disease, ...

INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, ...